Minerva Neurosciences NERV shares are trading higher after the company announced results from the 40-week open-label extension of its phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia.
Minerva Neurosciences' stock has been rising Wednesday, up 17.48% to a price of $2.79. The stock's current volume for the day is 51.07 million, which is approximately 10699.38% of its previous 30-day average volume of 477.33 thousand.
The 50-day moving average price of Minerva Neurosciences's stock was $2.74 when this article was published. The stock reached a high of $15.21 and a low of $1.81 in the past 52 weeks.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
